Showing 461-470 of 3494 results for "".
- AAD Issues Statement on Drinkable Sunscreenhttps://practicaldermatology.com/news/20140523-aad_issues_statement_on_drinkable_sunscreen/2459231/
- Free Drug Samples May Influence Prescribing Habitshttps://practicaldermatology.com/news/20140417-free_drug_samples_may_influence_prescribing_habits/2459266/Results of a study published online on April 16 in JAMA Dermatology found that the availability of free medication samples in dermatology offices appears to change pr
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (
- Galen Acquires Local Dermal Analgesia Drug Synerahttps://practicaldermatology.com/news/20130716-galen_acquires_local_dermal_analgesia_drug_synera/2459495/Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin t
- Health-Conscious Women 60% More Likely to Prefer Expensive Brand-Name Drugshttps://practicaldermatology.com/news/20121025-health-conscious_women_60_more_likely_to_prefer_expensive_brand-name_drugs/2459691/The consumer market research firm Scarborough analyzed "Health-Conscious Women," defined by Scarborough as American adult women who agree that they go to the doctor regularly for checkups, generally feel they eat right, and follow a regular exercise routine. Health-Conscious Women make up 16 percent
- FDA Extends Action Date For Tofacitinib New Drug Application By Three Monthshttps://practicaldermatology.com/news/20120824-us_food_and_drug_administration_extends_action_date_for_tofacitinib_new_drug_application_by_three_months/2459748/
- FDA Approves First Treatment for Ataxia-Telangiectasiahttps://practicaldermatology.com/news/fda-approves-first-treatment-for-ataxia-telangiectasia/2488536/The US Food and Drug Administration (FDA) has approved Aqneursa (levacetylleucine; IntraBio) for the treatment of adults and pediatric patients with ataxia-telangiectasia (A-T) who weigh at least 15 kg, providing the first FDA-approved treatment for the rare multisystem disorder. A-T is pr
- Zasocitinib Could Raise the Efficacy Bar for Oral Psoriasis Treatment, Takeda Doctor Sayshttps://practicaldermatology.com/news/zasocitinib-could-raise-the-efficacy-bar-for-oral-psoriasis-treatment-takeda-doctor-says/2488520/Following the US Food and Drug Administration's decision to grant Priority Review to zasocitinib (TAK-279) for adults with moderate-to-severe plaque psoriasis, Chinwe Ukomad
- LEO Pharma Closes Dersimelagon Acquisition as FDA Accepts NDAhttps://practicaldermatology.com/news/leo-pharma-closes-dersimelagon-acquisition-as-fda-accepts-nda/2488489/LEO Pharma announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and granted Priority Review for the investigational treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The FDA has se
- Dupilumab Shows Sustained Effectiveness Through 3 Years in Pediatric Atopic Dermatitis: Analysishttps://practicaldermatology.com/news/dupilumab-shows-sustained-effectiveness-through-3-years-in-pediatric-atopic-dermatitis-analysis/2488475/Dupilumab demonstrated sustained effectiveness and a 3-year drug survival rate of 80.1% among pediatric patients with moderate to severe atopic dermatitis (AD) in a prospective real-world cohort published in JAMA Derma